The FDA’s PreCheck pilot is expanding its regulatory manufacturing workflow. The agency cleared the first flight of the program’s manufacturing pilot through seven biopharma companies, aiming to increase predictability for onshoring and streamline plant assessments ahead of specific product applications. In a parallel update, the FDA selected the initial cohort of seven companies for the pilot, including Eli Lilly and Regeneron and manufacturers Cellares and Fujifilm. Together, the actions signal the FDA is building a faster pre-submission path intended to reduce uncertainty and accelerate readiness assessments. For sponsors planning new manufacturing site entries or major lifecycle changes, the PreCheck framework could alter timing and planning for facility readiness and submission strategy.